Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease
申请人:——
公开号:US20030073707A1
公开(公告)日:2003-04-17
The invention provides compounds of Formula I:
1
wherein W
0
is a bicyclic moiety and is
2
These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful to treat diseases or conditions in which &agr;7 is known to be involved.
[EN] N-AZABICYCLO-SUBSTITUTED HETERO-BICYCLIC CARBOXAMIDES AS NACHR AGONISTS<br/>[FR] CARBOXAMIDES HETERO-BICYCLIQUES SUBSTITUES PAR N-AZABICYCLO, UTILISES EN TANT QU'AGONISTES DU RECEPTEUR DE L'ACETYLCHOLINE NICOTINIQUE
申请人:UPJOHN CO
公开号:WO2003037896A1
公开(公告)日:2003-05-08
The invention provides compounds of Formula (I), wherein Azabicyclo is I, II, III, IV, V, or VI; W0 is a bicyclic moiety and is (a), (b) or (c). These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which α7 is known to be involved.
Treatment of diseases with combinations of alpha 7 Nicotinic Acetylcholine Receptor agonists and other compounds
申请人:Corbett W. Jeffrey
公开号:US20050245504A1
公开(公告)日:2005-11-03
The present invention relates to compositions and methods to treat diseases or condition with an α7 nAChR full agonist and an inhibitor of cholinesterase, and or beta secretase and or gamma secretase.
N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
申请人:——
公开号:US20030176702A1
公开(公告)日:2003-09-18
The invention provides compounds of Formula I:
1
wherein Azabicyclo is
2
W
0
is a bicyclic moiety and is
3
These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which &agr;7 is known to be involved.
Treatment of attention defecit hyperactivity disorder
申请人:Rogers N. Bruce
公开号:US20050107425A1
公开(公告)日:2005-05-19
The present invention relates to compositions and methods to treat ADHD with an α7 nAChR full agonist and psychostimulants and/or monoamine reuptake inhibitors.